Pfizer has failed to clear the path for launching its Zirabev bevacizumab biosimilar in the UK once a six-month pediatric extension to a supplementary protection certificate based on the basic molecule patent protecting Roche’s Avastin cancer treatment expires in June next year. While the Arrow declaration sought by Pfizer – that certain acts would have been obvious in light of the state of the art at a particular date, thus precluding infringement – would “be of real commercial value to Pfizer”, UK Patents Court Judge Mr Justice Birss found that there was “no evidence of uncertainty about UK patent rights” to justify such a declaration.
UK Denies Pfizer’s Bid To Clear Path For Biosimilar Bevacizumab
Pfizer cannot get a UK Arrow declaration clearing it of infringement of pending bevacizumab patent applications through the biosimilar it plans to import from Belgium because Roche has already de-designated the UK parts of the applications.
More from Legal & IP
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.
• By
Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.